Aptamer Sciences Inc Logo

Aptamer Sciences Inc

Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.

291650 | KO

Overview

Corporate Details

ISIN(s):
KR7291650000
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로228번길 15 3동 301호(삼평동, 판교세븐벤처밸리1), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative aptamer-based technologies for therapeutics and diagnostics. The company leverages its proprietary integrated platforms to address unmet medical needs, primarily in oncology. Its therapeutic pipeline is centered on the ApDC™ (Aptamer-Drug Conjugate) platform, with lead candidate AST-201 advancing to clinical trials for treating GPC3-positive solid tumors like liver cancer. In the diagnostics segment, the company has developed and commercialized the AptoDetect™ platform, which includes AptoDetect™-Lung, an aptamer-based diagnostic kit for assessing lung cancer risk. Aptamer Sciences focuses on advancing its pipeline and forming strategic partnerships to commercialize its novel aptamer technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 84.4 KB
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 104.9 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 39.4 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 40.2 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 51.0 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 5.9 KB
2025-09-09 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 77.9 KB
2025-09-08 00:00
M&A Activity
경영권변경등에관한계약체결
Korean 15.1 KB
2025-08-20 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 10.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 891.5 KB
2025-07-03 00:00
Regulatory News Service
풍문또는보도에대한해명
Korean 4.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 745.9 KB
2025-04-07 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.2 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.5 KB

Automate Your Workflow. Get a real-time feed of all Aptamer Sciences Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptamer Sciences Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptamer Sciences Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.